retatrutide phase 2 trial obesity nejm 2023 results VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide Phase 3: TRIUMPH Program – Weight Regain after Stopping Obesity

TABLE 3 Appetite and behavioral peptides with abandoned or pharmacologically underexploited therapeutic development: native peptide pharmacology underdeveloped

Here's a measured look at the news and how it connects to the peptide landscape

The goal is modified activity that allows healing while preventing deconditioning and stiffness

Tao, X., West, A

Side Effects and Tolerability All three products share the gastrointestinal side effect profile associated with GLP-1 receptor agonism: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort are the most commonly reported adverse events, typically emerging during dose escalation and improving over time